Two biopharmaceutical companies will give $5 million and $500,000, respectively, to nonprofit organizations in the United States and abroad that are responding to the growing monkeypox outbreak. The pledges come as the early philanthropic response to the disease, which disproportionately affects LGBTQ people, has been fairly muted compared with the early days of COVID-19.
Gilead Sciences, which produces HIV medicines, is providing up to $5 million to nonprofits in the United States and abroad that are working to prevent and treat monkeypox. It will give $350,000 each to GLAAD, the Human Rights Campaign, the National Black Justice Coalition, and the National Center for Lesbian Rights. Those nonprofits will collaborate on a public education campaign and create materials about vaccination, treatment, and prevention that can be shared with organizations across the country.
Gilead will also give another $500,000 to NMAC, a nonprofit working to end the HIV epidemic, which will use the money to lead an advocacy campaign focused on ensuring monkeypox vaccines are distributed equitably and to fight vaccine hesitancy. The remaining $3 million will be distributed in grants of up to $50,000 to Gilead’s grantees outside the U.S. that are also seeing a rise in monkeypox cases.
Read this story now for free
To continue reading, sign up for our newsletter and get unlimited access to WABE.org
You can select your preferences for news and local content. We will never share your email address. Learn how your newsletter sign-up will support WABE and Public Media
